Although VX-497 missed its target for viral load reduction in a Phase II trial in hepatitis C virus infection, Vertex Pharmaceuticals Inc. is looking forward to a longer Phase III study, with a more closely defined patient population. The company thus believes that it can offset the shortcomings of the Phase II study's short duration and patient population with highly variable HCV RNA levels upon entry, and give VX-497 a better chance of showing